Tocilizumab biosimilar (Livzon Group)

托珠单抗生物类似药（丽珠集团）

Report date: 2023/12/29 15:09:35

Base Information

Drug NameTocilizumab biosimilar (Livzon Group)
Drug Alias Name重组人源化抗人IL-6R单克隆抗体注射液安维泰LZM-008
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsArthritis, Rheumatoid
Approved Indications in ChinaArthritis, Rheumatoid
Original Approved Country/TerritoryMainland China
Original Approved Date2023/01/18
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesLivzon Pharmaceutical Group Inc
China Registration ClassN/A

Develop Information

Active CompaniesLivzon Mabpharm Inc
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeL04AC07
Related LinksWikipediaDrugBankKEGG